Traws Pharma通过多份监管提交推进抗病毒管道

2025-06-30 18:44

Traws Pharma (NASDAQ:TRAW) on Monday announced multiple regulatory submissions related to its antiviral pipeline.
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere.
Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu.
Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID.
Traws Pharma (NASDAQ:TRAW) -6.3% premarket.

More on Traws Pharma